Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 222


A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis.

Cowell SJ, Newby DE, Prescott RJ, Bloomfield P, Reid J, Northridge DB, Boon NA; Scottish Aortic Stenosis and Lipid Lowering Trial, Impact on Regression (SALTIRE) Investigators.

N Engl J Med. 2005 Jun 9;352(23):2389-97.


Progressive coronary calcification despite intensive lipid-lowering treatment: a randomised controlled trial.

Houslay ES, Cowell SJ, Prescott RJ, Reid J, Burton J, Northridge DB, Boon NA, Newby DE; Scottish Aortic Stenosis and Lipid Lowering Therapy, Impact on Regression trial Investigators.

Heart. 2006 Sep;92(9):1207-12. Epub 2006 Jan 31.


Intensive lipid lowering with atorvastatin in patients with stable coronary disease.

LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, Gotto AM, Greten H, Kastelein JJ, Shepherd J, Wenger NK; Treating to New Targets (TNT) Investigators.

N Engl J Med. 2005 Apr 7;352(14):1425-35. Epub 2005 Mar 8.


Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial.

Nissen SE, Tuzcu EM, Schoenhagen P, Brown BG, Ganz P, Vogel RA, Crowe T, Howard G, Cooper CJ, Brodie B, Grines CL, DeMaria AN; REVERSAL Investigators.

JAMA. 2004 Mar 3;291(9):1071-80.


Effect of hydroxymethylglutaryl coenzyme a reductase inhibitors on the progression of calcific aortic stenosis.

Novaro GM, Tiong IY, Pearce GL, Lauer MS, Sprecher DL, Griffin BP.

Circulation. 2001 Oct 30;104(18):2205-9.


Effects of rosuvastatin on progression of stenosis in adult patients with congenital aortic stenosis (PROCAS Trial).

van der Linde D, Yap SC, van Dijk AP, Budts W, Pieper PG, van der Burgh PH, Mulder BJ, Witsenburg M, Cuypers JA, Lindemans J, Takkenberg JJ, Roos-Hesselink JW.

Am J Cardiol. 2011 Jul 15;108(2):265-71. doi: 10.1016/j.amjcard.2011.03.032. Epub 2011 May 10.


Prognosis and risk factors in patients with asymptomatic aortic stenosis and their modulation by atorvastatin (20 mg).

Dichtl W, Alber HF, Feuchtner GM, Hintringer F, Reinthaler M, Bartel T, Süssenbacher A, Grander W, Ulmer H, Pachinger O, Müller S.

Am J Cardiol. 2008 Sep 15;102(6):743-8. doi: 10.1016/j.amjcard.2008.04.060. Epub 2008 Jul 2.


Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease.

Nissen SE, Tuzcu EM, Schoenhagen P, Crowe T, Sasiela WJ, Tsai J, Orazem J, Magorien RD, O'Shaughnessy C, Ganz P; Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) Investigators.

N Engl J Med. 2005 Jan 6;352(1):29-38.


Effect of intensive versus standard lipid-lowering treatment with atorvastatin on the progression of calcified coronary atherosclerosis over 12 months: a multicenter, randomized, double-blind trial.

Schmermund A, Achenbach S, Budde T, Buziashvili Y, Förster A, Friedrich G, Henein M, Kerkhoff G, Knollmann F, Kukharchuk V, Lahiri A, Leischik R, Moshage W, Schartl M, Siffert W, Steinhagen-Thiessen E, Sinitsyn V, Vogt A, Wiedeking B, Erbel R.

Circulation. 2006 Jan 24;113(3):427-37. Epub 2006 Jan 16.


Intensive versus moderate lipid lowering with statins after acute coronary syndromes.

Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM; Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators.

N Engl J Med. 2004 Apr 8;350(15):1495-504. Epub 2004 Mar 8. Erratum in: N Engl J Med. 2006 Feb 16;354(7):778.


Atorvastatin therapy is not associated with slowing the progression of aortic stenosis: findings of a randomized controlled trial.

Panahi Y, Sahebkar A, Taghipour HR, Dadjou Y, Pishgoo B, Rakhshankhah AS.

Clin Lab. 2013;59(3-4):299-305.


The influence of statins on levels of calcification biomarkers in patients with aortic sclerosis or mild aortic stenosis.

Dimitrow PP, Jawień M, Gackowski A.

J Heart Valve Dis. 2011 Jan;20(1):18-22.


High-dose atorvastatin after stroke or transient ischemic attack.

Amarenco P, Bogousslavsky J, Callahan A 3rd, Goldstein LB, Hennerici M, Rudolph AE, Sillesen H, Simunovic L, Szarek M, Welch KM, Zivin JA; Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators.

N Engl J Med. 2006 Aug 10;355(6):549-59.


Effects of atorvastatin on bone in postmenopausal women with dyslipidemia: a double-blind, placebo-controlled, dose-ranging trial.

Bone HG, Kiel DP, Lindsay RS, Lewiecki EM, Bolognese MA, Leary ET, Lowe W, McClung MR.

J Clin Endocrinol Metab. 2007 Dec;92(12):4671-7. Epub 2007 Aug 28.


A comparison of simvastatin and atorvastatin up to maximal recommended doses in a large multicenter randomized clinical trial.

Illingworth DR, Crouse JR 3rd, Hunninghake DB, Davidson MH, Escobar ID, Stalenhoef AF, Paragh G, Ma PT, Liu M, Melino MR, O'Grady L, Mercuri M, Mitchel YB; Simvastatin Atorvastatin HDL Study Group.

Curr Med Res Opin. 2001;17(1):43-50.


The effect of moderate-dose versus double-dose statins on patients with acute coronary syndrome in China: Results of the CHILLAS trial.

Zhao SP, Yu BL, Peng DQ, Huo Y.

Atherosclerosis. 2014 Apr;233(2):707-12. doi: 10.1016/j.atherosclerosis.2013.12.003. Epub 2014 Jan 8.


A randomized, double blind, placebo-controlled pilot trial of the safety and efficacy of atorvastatin in children with elevated low-density lipoprotein cholesterol (LDL-C) and type 1 diabetes.

Canas JA, Ross JL, Taboada MV, Sikes KM, Damaso LC, Hossain J, Caulfield MP, Gidding SS, Mauras N.

Pediatr Diabetes. 2015 Mar;16(2):79-89. doi: 10.1111/pedi.12245. Epub 2014 Nov 22.


A placebo-controlled trial examining atorvastatin in dyslipidemic patients undergoing CAPD.

Harris KP, Wheeler DC, Chong CC; Atorvastatin in CAPD Study Investigators. Continuous ambulatory peritoneal dialysis.

Kidney Int. 2002 Apr;61(4):1469-74.

Supplemental Content

Support Center